ConductScience.org, home

Paper40927638

Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.

Shi Z and 15 others. RSC Med Chem, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization. Papers, record 40927638. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40927638

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.
PubMed
Journal
RSC Med Chem
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-09-18
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shi ZZhe
2Guddneppanavar RRajsekhar
3Winn BABlake A
4MacDonough MTMatthew T
5George CSClinton S
6Wang YYifan
7Zimmer MMark
8Gerberich JJeni
9Winters AAlex
10Lin EElisa
11Maguire CJCasey J
12Ford JJacob
13Hamel EErnest
14Mason RPRalph P
15Trawick MLMary Lynn
16Pinney KGKevin G

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA140674NCI NIH HHSUnited StatesR01CA140674PubMed and NIHNIH RePORTER
S10 RR024757NCRR NIH HHSUnited StatesS10RR024757PubMed and NIHNIH RePORTER
R01 CA244579NCI NIH HHSUnited StatesR01CA244579PubMed and NIHNIH RePORTER
P30 CA142543NCI NIH HHSUnited StatesP30CA142543PubMed and NIHNIH RePORTER
R01 CA238624NCI NIH HHSUnited StatesR01CA238624PubMed and NIHNIH RePORTER
HHSN261200800001CCCR NIH HHSUnited StatesPubMedPubMed
HHSN261200800001ENCI NIH HHSUnited StatesPubMedPubMed

Download CSV of grants

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126852340Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.Bioorg Med Chem2016https://conductscience.org/library/papers/26852340PubMed
223063837New strategies for targeting the hypoxic tumour microenvironment in breast cancer.Cancer Treat Rev2013https://conductscience.org/library/papers/23063837PubMed
311181500P450 enzyme expression patterns in the NCI human tumor cell line panel.Drug Metab Dispos2001https://conductscience.org/library/papers/11181500PubMed
46115675Stabilization of the colchicine-binding activity of tubulin by organic acids.Biochim Biophys Acta1981https://conductscience.org/library/papers/6115675PubMed
516784022Current development status of small-molecule vascular disrupting agents.Curr Opin Investig Drugs2006https://conductscience.org/library/papers/16784022PubMed
633921719Podophyllotoxin: History, Recent Advances and Future Prospects.Biomolecules2021https://conductscience.org/library/papers/33921719PubMed
730429970Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.Medchemcomm2018https://conductscience.org/library/papers/30429970PubMed
822184053Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.Clin Cancer Res2012https://conductscience.org/library/papers/22184053PubMed
926297733Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.Cancer Res2015https://conductscience.org/library/papers/26297733PubMed
1024183586Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.Bioorg Med Chem2013https://conductscience.org/library/papers/24183586PubMed
117752190Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a)J Med Chem1995https://conductscience.org/library/papers/7752190PubMed
129572894Antineoplastic agents. 379. Synthesis of phenstatin phosphate.J Med Chem1998https://conductscience.org/library/papers/9572894PubMed
1320051957Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.Br J Cancer2010https://conductscience.org/library/papers/20051957PubMed
1420501808Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity.Mol Cancer Ther2010https://conductscience.org/library/papers/20501808PubMed
1510682679NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.Br J Cancer2000https://conductscience.org/library/papers/10682679PubMed
1631002225Kinetics-Based Measurement of Hypoxia in Living Cells and Animals Using an Acetoxymethyl Ester Chemiluminescent Probe.ACS Sens2019https://conductscience.org/library/papers/31002225PubMed
1732196334Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.J Nat Prod2020https://conductscience.org/library/papers/32196334PubMed
1821376230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed
1923845143Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Chin J Cancer2014https://conductscience.org/library/papers/23845143PubMed
209537252Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.Cancer Res1998https://conductscience.org/library/papers/9537252PubMed

See all 81 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40927638

GET https://conductscience.org/api/papers/v1/40927638/references?page=2